CaCC Inhibitors
1 drugsAbout CaCC
CaCC's biological function and mechanism are not detailed in the provided context.
There is currently no genetic evidence available to support CaCC as a therapeutic target for any specific disease.
CaCC is targeted by one approved small molecule drug, MYTESI, marketed by NAPO PHARMS INC for other therapeutic areas.
Top CaCC Drugs
NAPO PHARMS INC is the only company with an approved drug targeting CaCC.
Low competition may indicate high entry barriers or limited market potential.
CaCC Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets CaCC, using small molecule modality.
Exploring alternative modalities like antibodies or biologics could provide differentiation.
CaCC Clinical Trials 9 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on CaCC. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 2 | 4 | 2 | 0 | 2 | 100% |
| Phase 3 | 2 | 2 | 0 | 0 | 100% |
| Phase 4 | 3 | 2 | 1 | 0 | 67% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
CaCC Drug Approval Timeline (2012 - 2012)
The first and only drug approval for CaCC was MYTESI in 2012.
The lack of recent approvals suggests a saturated market or limited innovation in this area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 7 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on CaCC. A trial counts if an approved drug acting on CaCC is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.